Apr 23, 2026 Log in

News

[Peijia Bio] PL001 (CD19 CAR-T) Efficacy Passes Phase II Interim Analysis with Statistical Significance

Q: Where is the primary source?

PR Times: https://mops.twse.com.tw/material/twse-6949-2026-04-23-6fe69e08

Citation-Grade Primary-source linked Schema.org verified NQ 0 / 100

Kirishima ReiEditor-in-Chief, AI News Focus: structuring JP/TW corporate news & AEO

Published Apr 23, 2026 9:00 AM ・ Updated Jun 13, 2026 8:26 AM ・ 2 min read ・ Source: PR Times

Show contents

⚡ Key Points

Peijia Bio's CAR-T therapy PL001 achieved significant success in its Phase II interim analysis for B-cell lymphoma, paving the way for accelerated NDA approval in Taiwan.

Peijia Bio's CAR-T therapy PL001 achieved significant success in its Phase II interim analysis for B-cell lymphoma, paving the way for accelerated NDA approval in Taiwan.

PRIMARY SOURCE PR Times View source Distributor: PR Times
Published: Apr 23, 2026

1. Date: 2026/04/23. 2. Drug: PL001 (CD19 CAR-T). 5. Phase II Results: The interim analysis showed statistical significance (p < 0.0001), exceeding the CDE requirement (p < 0.0087). 14 out of 23 subjects met the primary efficacy indicator (CR+PR). Future Plan: The company will submit an interim report and apply for an NDA under the 'Accelerated Approval' mechanism in Taiwan. 7. Market: The global CAR-T market is expected to reach $6B by 2025 and over $10B by 2030.

FACT BOX

Source: PR Times
Category: News
Products / services: PL001 (CD19 CAR-T)

Editorial & Verification Standards

The Washin AI News desk structures and reviews this article under the following standards.

Start only from primary sources (official PR, disclosures, wire services)
Numbers and proper nouns machine-checked against the source (number-completeness check)
Company names and tickers verified via registry (Registry/TWSE/Wikidata)
No speculation; nothing stated that is not in the source

Read the full editorial policy →

Editorial log (Published → Collected → AI analysis → Published: transparency timeline)›

Announced　Apr 23, 2026 9:00 AM — Distributor PR Times
Collected　Apr 24, 2026 8:00 AM
AI structured & analyzed　Apr 24, 2026 8:23 AM
Desk-reviewed & published　Apr 23, 2026 9:00 AM

FAQ

What are the key facts in this article?

Peijia Bio's CAR-T therapy PL001 achieved significant success in its Phase II interim analysis for B-cell lymphoma, paving the way for accelerated NDA approval in Taiwan.

Where is the primary source?

PR Times: https://mops.twse.com.tw/material/twse-6949-2026-04-23-6fe69e08

When was it published?

Apr 23, 2026

Cite this article — HOW TO CITE

Washin AI News Desk“[Peijia Bio] PL001 (CD19 CAR-T) Efficacy Passes Phase II Interim Analysis with Statistical Significance”AI News by Washin Village（和心村）, Apr 23, 2026. https://aeo.washinmura.jp/ai/%E6%B2%9B%E7%88%BE%E7%94%9F%E9%86%AB-%E5%89%B5/en/news/2026-04-23-peijia-bio-pl001-cd19-car-t-efficacy-pas-2

AI CRAWLER ACTIVITY

as of Jun 28, 2026

AI crawler visits to this article (cumulative)41 bots

Site-wide cumulative

ClaudeBot

bot_visits_summary

4080k

last Jun 28, 2026

GPTBot

bot_visits_summary

2486k

last Jun 28, 2026

Google AI

bot_visits_summary

1782k

last Jun 28, 2026

Bingbot

bot_visits_summary

1623k

last Jun 28, 2026

Googlebot

bot_visits_summary

1289k

last Jun 28, 2026

Meta AI

bot_visits_summary

528k

last Jun 28, 2026

※ Only measured values from bot_visits_summary / crawler_url_hits are shown. Article-level zero counts are shown as measuring.

Washin AI News（AI News by Washin Village（和心村））

An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.

Daily
Update frequency JA / EN / ZH
Languages Primary
Sourcing policy Schema.org
Structured verification

About the publisher IDA llms.txt

Get your announcement indexed as AI-citable structured news.
Primary-source links, three languages, Schema.org verified.Talk to us about coverage →

← 沛爾生醫-創 Back to newsroom (128)

Copied